Human epidermal growth factor receptor 2 overexpression is associated with high-grade tumors in upper tract urothelial carcinoma
Authors:
Open Access
- 24 October 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 16 (10) , 110047
Abstract
BACKGROUND Human epidermal growth factor receptor 2 (HER2) plays pivotal roles in cellular proliferation, survival, and differentiation of several malignancies. Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy. The clinical and molecular significance of HER2 expression level in UTUC remains poorly characterized vs bladder cancer. AIM To comprehensively evaluate HER2 expression patterns and their association with UTUC patients’ clinicopathological features. METHODS Data were retrospectively collected from patients diagnosed with UTUC at The First Affiliated Hospital of Guangxi Medical University between January 2023 and December 2024. HER2 status was evaluated by immunohistochemistry in 145 UTUC patients who met the inclusion criteria. Its associations with tumor grade, tumor stage, and other clinicopathological parameters were assessed. The χ 2 test or Fisher’s exact test, along with univariate and multivariate logistic regression analyses, were performed to determine the influences of clinicopathological factors on HER2 expression. RESULTS HER2 positivity was significantly associated with high tumor grade (P = 0.003), while other variables, including sex, anatomical tumor location, pathological T stage, Ki-67 proliferation index, nodal metastasis status, lymphovascular invasion, and tumor laterality failed to demonstrate statistically significant correlations. These findings were further substantiated through univariate logistic regression modeling, yielding an odds ratio of 3.56 [95% confidence interval (CI): 1.30-9.75; P = 0.013] for the association between high tumor grade and HER2 positivity. Importantly, this relationship remained robust (hazard ratio = 3.42, 95%CI: 1.22-9.60; P = 0.019) even after implementing multivariate logistic regression analysis. With a median follow-up time of 8 months (interquartile range, 4-14) months, 14 patients experienced intravesical recurrence after radical nephroureterectomy. Certain patient characteristics, such as HER2-negative, male sex, high-grade tumors, and luminal phenotype, were associated with a higher risk of intravesical recurrence. CONCLUSION In UTUC, HER2 overexpression is closely associated with tumor dedifferentiation (high grade), while it does not correlate with conventional indicators of disease progression, indicating that HER2 may serve a distinct biological function in this cancer type.Keywords
This publication has 28 references indexed in Scilit:
- Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in ChinaVirchows Archiv, 2025
- Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial CarcinomaCurrent Urology Reports, 2024
- HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest ChinaWorld Journal of Urology, 2024
- Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancerBreast Cancer Research and Treatment, 2023
- Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted TherapyClinical Genitourinary Cancer, 2023
- Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implicationsVirchows Archiv, 2018
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer2017
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyCancer Cell, 2014
- The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor ThrombusEuropean Urology, 2011